Page 35 - FLIPBOOK
P. 35

Cardiovascular risk profiles of GnRH agonists and antagonists:


      real-world analysis from UK general practice




          ▪      In an analysis of a UK primary care database of N=9,081 patients aged ≥401:

          ▪      Significantly fewer patients on antagonists had a CV event, compared with patients on LHRH


                 agonists (6.9% vs 17.7%, p=0.01)*






































                                   CV: cardiovascular; LHRH, luteinising hormone-releasing hormone.; *More patients on atagonists had pre-existing CVD at
                                   baseline compared with patients on agonists. 1.) Davey P and Kirby M. J Urol. 2020;203(4S):e250–e251.
   30   31   32   33   34   35   36   37   38   39   40